NMRA
Neumora TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Operating peers and competitors
Source-backed product markets and frozen research comparisons. Valuation comparators remain in the existing peer table.
Loading market evidence...
Research comparisons do not establish forecast usefulness or trading returns.
Compare shared product markets
Membership only; no portfolio weights or estimated losses.
+
Peers tracked
9
U.S. public peers
Grade Position
Above peers
vs peer average
NMRA vs peer average
75/100
NMRA vs. peer average (B vs. D)
Grade spread
B 1 · C 4 · D 2 · F 2
Graded peers loaded
Coverage
9 graded
100% of tracked
Peer overview
AXSM is the first available peer comparator.
Axsome's AXS-05 is being developed for Alzheimer's disease agitation, directly overlapping NMRA-511's intended indication. Axsome has a different mechanism, later development and commercial operations, so it is an indication comparator, not a valuation multiple for Neumora ([Axsome pipeline](https://www.axsome.com/axs-portfolio/pipeline/about-axs-05/)).
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
NMRA
Neumora Therapeutics
AXSM
Axsome Therapeutics
Grade
B
B
Momentum
98
8
Value
41
41
Sentiment
71
83
Setup Bias
Net —
-
Market Cap
-
-
Posture
Constructive
Constructive
Grade position vs AXSM
NMRA / AXSM
Grade Position
Above peers
NMRA vs. peer average (B vs. D)
75/100
Momentum
98
NMRAValue
41
NMRASentiment
71
AXSMRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs NMRA
AXSM is the first peer returned for this comparison set.